Orexo: Zubsolv Rx Data week 52

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.78% (5.84%), 4-week rolling average. The total number of Zubsolv tablets sold week 52 (51) reaching 290,099 (345,239). Zubsolv prescriptions (TRx) recorded a market share of 5.67% (5.76%), 4-week rolling average. Total number of prescriptions reaching 10,276 (11,852) during the week.

The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 10.9% (10.3%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 9.6% (9.7%) (4-week rolling average). Next Zubsolv prescription data update will be released the 16th of January

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-24 Update
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update